NYC Healthcare News

Idera reports $6.0 million net loss for fourth quarter 2010

February 20, 2016

In December 2010, Idera scientists presented data at the 52nd Annual American Society for Hematology Meeting showing that IMO-4200, when administered in combination with approved cancer therapy agents in preclinical lymphoma models, resulted in improved antitumor activity, increased survival compared to single-agent treatments, and immune activation consistent with the TLR7/TLR8 mechanism of action.The Company intends to outline a development program strategy and timeline for IMO-4200 in the treatment of hematological malignancies during the first half of 2011.

TLR3 Agonists

In October 2010, Idera introduced a novel class of double-stranded RNA-based compounds that act as specific TLR3 agonists. Idera's proprietary TLR3 agonists showed potent activity when used as a vaccine adjuvant in preclinical studies. Idera plans to expand preclinical evaluation of these compounds.

Partnered Programs

EMD 1201081 (IMO-2055) for Cancer Treatment

IMO-2055, a TLR9 agonist, is being developed by Merck KGaA as a novel immunotherapy for the treatment of cancer under an exclusive, worldwide license agreement established between Idera and Merck KGaA to research, develop and commercialize Idera's TLR9 agonists for the treatment of cancer, excluding cancer vaccines. Merck KGaA refers to IMO-2055 as EMD 1201081.

Merck KGaA is currently conducting four clinical trials of EMD 1201081 in combination with other cancer therapeutic agents:

Phase 2 Clinical Trial in Second-Line Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) evaluating EMD 1201081 in combination with Erbitux? Phase 1b Clinical Trial in First-Line Patients with Recurrent/Metastatic SCCHN evaluating EMD 1201081 in combination with Erbitux? and chemotherapy Phase 1b clinical trial in non-small cell lung cancer evaluating EMD 1201081 in combination with Tarceva? and Avastin? Phase 1b clinical trial in colorectal cancer evaluating EMD 1201081 in combination with Erbitux? and chemotherapy

During 2010, Idera received milestone payments of $8.2 million in connection with initiation of the two SCCHN trials.

TLR7, 8 and 9 Agonists as Vaccine Adjuvants

Idera and Merck & Co., Inc. entered into an exclusive license and research collaboration agreement in December 2006 to research, develop and commercialize vaccine products containing the Company's TLR7, 8, and 9 agonists in the fields of oncology, infectious diseases and Alzheimer's disease. As part of the agreement, the two companies engaged in a research collaboration to generate novel agonists targeting TLR7 and TLR8 incorporating both Merck and Idera chemistry for use in the licensed fields. The research phase of the collaboration has concluded.

During 2010, Merck scientists published a paper entitled "Synthesis and immunological activities of novel agonists of Toll-like receptor 9" in Cellular Immunology, March 2010 and made a presentation entitled "Novel TLR9 agonists combined with "alum" for use as vaccine adjuvants" at the Keystone Symposia meeting on Innate Immunity in June 2010.

2010 Business Highlights

In August 2010, Idera issued 4 million units, each unit consisting of one share of common stock and a warrant to purchase 0.40 of a share of common stock, in a registered direct offering resulting in net proceeds to the Company of $14.1 million. In 2010, the Company was issued 20 new U.S. and foreign patents related to its Immune Modulatory Oligonucleotide (IMO?) technologies. Presently, the Company's intellectual property portfolio contains over 500 patents and patent applications worldwide, including over 300 patents and patent applications covering the Company's IMO? technologies and more than 225 patents and patent applications owned or licensed by Idera covering other nucleic acid-based compounds and methods of their use. In 2010, Idera appointed two new members to its Board of Directors: Malcolm MacCoss, Ph.D., former Group Vice President for Chemical Research at the Schering-Plough Research Institute and former Vice President of Basic Chemistry and Drug Discovery Sciences at Merck & Co., and Eve Slater, M.D., F.A.C.C., former Senior Vice President for Worldwide Policy at Pfizer, Inc. and former Assistant Secretary for Health for the U.S. Department of Health and Human Services.

SOURCE Idera Pharmaceuticals, Inc.